Education
About Us
Working with TipRanks
Follow Us
Tenet Healthcare Corp. (THC)
:THC
THC Analyst Ratings
Strong Buy
13 Buy
1 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
THC Stock 12 Month Forecast
Average Price Target
$169.15
▲(36.64% Upside)
| Highest Price Target$185.00 | Average Price Target$169.15 | Lowest Price Target$136.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
RBC Capital
Reiterated
04/11/25
Barclays
Reiterated
04/10/25
Guggenheim
Initiated
04/08/25
Cantor Fitzgerald
Reiterated
04/03/25
Jefferies
Reiterated
04/02/25
Morgan Stanley
Initiated
03/26/25
TD Cowen
Initiated
02/28/25
Truist Financial
Reiterated
02/27/25
TD Securities
Initiated
02/26/25
Leerink Partners
Reiterated
02/24/25
KeyBanc
$185
Buy
49.45%
Upside
Reiterated
02/13/25
KeyBanc Remains a Buy on Tenet Healthcare (THC)
Mizuho Securities
―
Buy
―
Reiterated
02/12/25
Analysts Offer Insights on Healthcare Companies: Atricure (NASDAQ: ATRC), Kala Pharmaceuticals (NASDAQ: KALA) and Tenet Healthcare (NYSE: THC)
Wells Fargo
$150
Hold
21.17%
Upside
Reiterated
02/12/25
Mixed Performance and Future Outlook Lead to Cautious Hold Rating for Tenet Healthcare
Bank of America Securities
$165
Buy
33.29%
Upside
Reiterated
02/12/25
Tenet Healthcare's Strong Financial Performance and Strategic Shift Drive Buy RatingWe reiterate Buy on solid results and mix shift to the faster growing ASC business. Beat, Hospital vols accelerated but ASC vols worse Adj EBITDA was $39m (4%) above consensus/ guide midpoint. Hospital vols accelerated but Ambulatory volumes decelerated and were below expectations (pricing was better). EBITDA guide 1% better on better margins THC guided to Revs slightly below consensus with EBITDA 1% above consensus/our est. with better ASC offsetting worse Hospital guide. Ex $35m from TN DPP, consolidated EBITDA guide midpoint is in line. Margins to be 19.3-19.9%, above cons est of 19.1%. Q1 EBITDA guide implies $978-1,019m, in line with Cons of $1.0bn. Adj free cash flow (FCF) guide of $1.9-2.1bn is below our est of $2.3bn, but it is a nice growth from $1.3bn in 2024. Adj FCF after NCI payments to be $1.15-1.3bn, more than doubling y/y.
Goldman Sachs
$196→$140
Hold
13.09%
Upside
Downgraded
12/16/24
Tenet Healthcare downgraded to Neutral from Buy at Goldman SachsTenet Healthcare downgraded to Neutral from Buy at Goldman Sachs
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
RBC Capital
Reiterated
04/11/25
Barclays
Reiterated
04/10/25
Guggenheim
Initiated
04/08/25
Cantor Fitzgerald
Reiterated
04/03/25
Jefferies
Reiterated
04/02/25
Morgan Stanley
Initiated
03/26/25
TD Cowen
Initiated
02/28/25
Truist Financial
Reiterated
02/27/25
TD Securities
Initiated
02/26/25
Leerink Partners
Reiterated
02/24/25
KeyBanc
$185
Buy
49.45%
Upside
Reiterated
02/13/25
KeyBanc Remains a Buy on Tenet Healthcare (THC)
Mizuho Securities
―
Buy
―
Reiterated
02/12/25
Analysts Offer Insights on Healthcare Companies: Atricure (NASDAQ: ATRC), Kala Pharmaceuticals (NASDAQ: KALA) and Tenet Healthcare (NYSE: THC)
Wells Fargo
$150
Hold
21.17%
Upside
Reiterated
02/12/25
Mixed Performance and Future Outlook Lead to Cautious Hold Rating for Tenet Healthcare
Bank of America Securities
$165
Buy
33.29%
Upside
Reiterated
02/12/25
Tenet Healthcare's Strong Financial Performance and Strategic Shift Drive Buy RatingWe reiterate Buy on solid results and mix shift to the faster growing ASC business. Beat, Hospital vols accelerated but ASC vols worse Adj EBITDA was $39m (4%) above consensus/ guide midpoint. Hospital vols accelerated but Ambulatory volumes decelerated and were below expectations (pricing was better). EBITDA guide 1% better on better margins THC guided to Revs slightly below consensus with EBITDA 1% above consensus/our est. with better ASC offsetting worse Hospital guide. Ex $35m from TN DPP, consolidated EBITDA guide midpoint is in line. Margins to be 19.3-19.9%, above cons est of 19.1%. Q1 EBITDA guide implies $978-1,019m, in line with Cons of $1.0bn. Adj free cash flow (FCF) guide of $1.9-2.1bn is below our est of $2.3bn, but it is a nice growth from $1.3bn in 2024. Adj FCF after NCI payments to be $1.15-1.3bn, more than doubling y/y.
Goldman Sachs
$196→$140
Hold
13.09%
Upside
Downgraded
12/16/24
Tenet Healthcare downgraded to Neutral from Buy at Goldman SachsTenet Healthcare downgraded to Neutral from Buy at Goldman Sachs
Best Analysts Covering Tenet Healthcare
Which Analyst Should I Follow If I Want to Buy THC and Sell After:
1 Month
xxx
Success Rate
15/19 ratings generated profit
Average Return
+8.41%
reiterated a xxx
rating last month
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 78.95% of your transactions generating a profit, with an average return of +8.41% per trade.
3 Months
xxx
Success Rate
10/14 ratings generated profit
Average Return
+11.34%
assigned a xxx
rating 9 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 71.43% of your transactions generating a profit, with an average return of +11.34% per trade.
1 Year
2 Years
xxx
Success Rate
29/36 ratings generated profit
Average Return
+61.75%
reiterated a xxx
rating 2 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 80.56% of your transactions generating a profit, with an average return of +61.75% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
THC Analyst Recommendation Trends
Rating
Dec 24
Jan 25
Feb 25
Mar 25
Apr 25
Strong Buy
0
0
0
0
0
Buy
21
10
18
17
20
Hold
3
3
2
1
1
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
24
13
20
18
21
Each month's total comprises the sum of three months' worth of ratings.
THC Financial Forecast
THC Stock Forecast FAQ
What is THC’s average 12-month price target, according to analysts?
Based on analyst ratings, Tenet Healthcare Corp.’s 12-month average price target is $169.15.
What is THC’s upside potential, based on the analysts’ average price target?
Tenet Healthcare Corp. has 36.64% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is THC a Buy, Sell or Hold?
Tenet Healthcare Corp. has a consensus rating of Strong Buy which is based on 13 buy ratings, 1 hold ratings and 0 sell ratings.
What is Tenet Healthcare Corp.’s price target?
The average price target for Tenet Healthcare Corp. is $169.15. This is based on 14 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $185.00 ,the lowest forecast is $136.00. The average price target represents 36.64% Increase from the current price of $123.79.
The highest analyst price target is $185.00 ,the lowest forecast is $136.00. The average price target represents 36.64% Increase from the current price of $123.79.
What do analysts say about Tenet Healthcare Corp.?
Tenet Healthcare Corp.’s analyst rating consensus is a Strong Buy. This is based on the ratings of 14 Wall Streets Analysts.
How can I buy shares of THC?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.